Minoxidil topique 5 % face à Minoxidil oral 1 mg

Topical minoxidil Oral minoxidil Degree of patient satisfaction Count Column N % Count Dissatisfied (1–3) 0 0.0 0 Low (4–5) 4 23.5 9 Medium (6–7) 10 58.8 13 High (8–10) 3 17.6 6

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Citation complémentaire (significativite)

0.0 0.717

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Topical minoxidil Oral minoxidil Degree of patient satisfaction Count Column N % Count Dissatisfied (1–3) 0 0.0 0 Low (4–5) 4 23.5 9 Medium (6–7) 10 58.8 13 High (8–10) 3 17.6 6

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Citation complémentaire (significativite)

0.0 0.717

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

Citation complémentaire (methode)

In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27)

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27)

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27) Heart rate (bpm)# 72 (8) 77 (8) <0.01 MAP (mmHg)# 93 (9) 91 (8) 0.23 Scalp pruritus## - 0 (-) * T0 vs. T24 ; # mean (sd); ## n (%); ### median (p25-p75);

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02 70 (9) 70 (8) 0.83 <0.01 89 (11) 89 (11) 0.97 0.51 - 5 (19) 0.02

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27) Heart rate (bpm)# 72 (8) 77 (8) <0.01 MAP (mmHg)# 93 (9) 91 (8) 0.23 Scalp pruritus## - 0 (-) * T0 vs. T24 ; # mean (sd); ## n (%); ### median (p25-p75);

Citation complémentaire (valeur)

Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02 70 (9) 70 (8) 0.83 <0.01 89 (11) 89 (11) 0.97 0.51 - 5 (19) 0.02

Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).